Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 250.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: -8.99%
• EPS Growth: -18.16%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 52
• Industry: Medical - Devices
• EPS (TTM): -0.04
• Shares Outstanding: 320,791,260
• 10 Day Avg. Volume: 236,000
• 30 Day Avg. Volume: 250,195
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$1.93
• Price Target Upside: 41.91% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 45 Neutral
• Price Target: AU$1.50 ▲(10.29% Upside)

Imricor Medical Systems' overall stock score is primarily impacted by its poor financial performance, with significant losses and high leverage posing major risks. Technical analysis suggests a neutral market position, while valuation metrics are weak due to negative earnings. The absence of earnings call and corporate events data limits further insights.

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Business Overview & Revenue Model

Company Description

Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States. The company's principal products include the Advantage-MR EP Recorder/Stimulator system, an EP recording system and integrated cardiac stimulator; Vision-MR Ablation Catheter, which is used as an indication for treating type I atrial flutter; and Vision-MR Dispersive Electrode that is used to minimize eddy currents induced on the conductive pads during MR scanning. It also performs contract research, as well as licenses its intellectual property for use in implantable devices. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.

How the Company Makes Money

Imricor Medical Systems, Inc. generates revenue through the sale of its MRI-compatible medical devices and systems to hospitals and healthcare facilities. The company leverages its proprietary technology to offer solutions that integrate with existing MRI systems, enhancing their utility for cardiac procedures. Revenue streams include the direct sale of devices, licensing agreements with medical institutions, and potential partnerships with MRI equipment manufacturers. The company's earnings are also influenced by the adoption of MRI-guided procedures in the medical community, driven by the growing demand for minimally invasive and precise cardiac treatments.

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Financial Statement Overview

Summary

Imricor Medical Systems is facing significant financial challenges, with negative gross and net profit margins, high leverage, and negative equity posing solvency risks. Persistent cash burn and negative operating cash flow highlight cash management issues.

Income Statement

Imricor Medical Systems has shown consistent revenue growth, increasing from $639,704 in 2019 to $959,424 in 2024. However, the company has been struggling with negative gross and net profit margins. The gross profit margin has been negative each year, with the most recent year at -96.32%, and the net profit margin has consistently been deeply negative, reaching -3094.85% in 2024. This indicates significant challenges in profitability and cost management. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

The company's balance sheet shows a worrisome trend with negative stockholders' equity of -$7,377,033 in 2024, indicating potential solvency risks. The debt-to-equity ratio is not meaningful due to negative equity, and while the total assets have increased over time, the leverage is high with total liabilities surpassing total assets. The equity ratio is also negative due to negative equity, highlighting financial instability.

Cash Flow

Imricor's cash flow situation is concerning, with a continuous negative operating cash flow and free cash flow, indicating cash burn. The free cash flow has been negative, reaching -$15,651,886 in 2024. Despite a positive financing cash flow from capital raises, the operating cash flow to net income ratio is negative, suggesting operating inefficiencies and challenges in generating cash from core operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	959.42K	615.57K	816.01K	696.27K	702.16K
Gross Profit	-924.12K	-1.12M	-1.53M	-1.90M	-397.67K
EBITDA	-15.55M	-21.87M	-16.47M	-18.93M	-11.62M
Net Income	-29.69M	-22.63M	-17.53M	-20.56M	-13.08M
Balance Sheet
Total Assets	21.62M	8.31M	13.70M	26.86M	33.57M
Cash, Cash Equivalents and Short-Term Investments	15.71M	831.52K	5.69M	18.52M	25.14M
Total Debt	21.35M	10.42M	4.49M	1.74M	1.39M
Total Liabilities	29.00M	17.06M	6.19M	4.46M	4.75M
Stockholders Equity	-7.38M	-12.83M	7.51M	22.40M	28.82M
Cash Flow
Free Cash Flow	-15.65M	-13.06M	-17.06M	-18.11M	-12.97M
Operating Cash Flow	-15.57M	-12.98M	-16.82M	-17.49M	-12.23M
Investing Cash Flow	-74.98K	-82.78K	-238.86K	-695.30K	-774.03K
Financing Cash Flow	30.33M	8.21M	3.94M	11.59M	33.02M

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.36
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IMR, the sentiment is Negative. The current price of 1.36 is below the 20-day moving average (MA) of 1.37, above the 50-day MA of 1.36, and below the 200-day MA of 1.40, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 48.67 is Neutral, neither overbought nor oversold. The STOCH value of 29.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IMR.

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTE	66 Neutral	AU$41.98M	22.28	98.18%	8.14%	11.93%	2.39%
ARX	63 Neutral	AU$224.27M	―	-4.06%	―	20.36%	64.81%
MDR	56 Neutral	AU$28.76M	110.00	-253.44%	―	-48.41%	-6520.00%
Sector *	51 Neutral	$7.95B	-0.38	-43.43%	2.22%	22.30%	-1.83%
EMV	46 Neutral	AU$170.18M	―	-70.55%	―	―	-257.32%
IMR	45 Neutral		―	-432.03%	―	-8.99%	-18.16%
OSL	43 Neutral	AU$22.78M	―	-385.20%	―	126.62%	33.53%

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Corporate Events

Imricor Medical Systems Achieves Key Regulatory Milestones and Expands European Sales Team

Imricor Medical Systems, Inc. reported significant progress in Q2 2025, with notable regulatory achievements including CE mark approvals for its Advantage-MR system and NorthStar mapping system under the new European Medical Device Regulation. The company also successfully performed the first-in-human ventricular ablation guided by real-time iCMR at Amsterdam University Medical Centre and commenced the VISABL-VT clinical trial. Financially, the company maintained a cash balance of US$50.3 million despite a temporary dip in cash receipts due to non-revenue generating clinical trial enrollments. Imricor’s European sales team expansion and ongoing regulatory advancements are expected to accelerate hospital adoption and commercial launches in Europe and the United States.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Advances Regulatory Approvals and Market Expansion

Imricor Medical Systems, Inc. has achieved significant regulatory milestones in Europe with the approval of its NorthStar system and second-generation products under the stringent EU-MDR, leading to a commercial launch and increased hospital engagement. In the United States, the company has submitted the NorthStar 510(k) Premarket Notification to the FDA, marking a strategic entry point into the US market. Despite some delays in the PMA approval process for certain products, Imricor’s prioritization of NorthStar’s approval is expected to align well with its sales cycle, supporting uninterrupted revenue growth and market expansion.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Medical Systems Issues New Equity Securities

Imricor Medical Systems, Inc. announced the issuance of 90,000 unquoted equity securities under an employee incentive scheme. This move is part of the company’s strategy to incentivize and retain talent, which could strengthen its operational capabilities and enhance its competitive position in the medical technology sector.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Medical Systems Announces Director’s Share Disposal

Imricor Medical Systems, Inc. announced a change in the interests of its director, Mr. Mark Tibbles, involving the disposal of 170,000 shares through an on-market trade and 73,380 shares via an off-market transfer. This adjustment in shareholding reflects a strategic decision by the director, potentially impacting the company’s stock dynamics and signaling a shift in personal investment strategy.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Announces Director’s Interest Change Under Equity Incentive Plan

Imricor Medical Systems, Inc. announced a change in the director’s interest, with Ms. Anita Messal acquiring 38,700 Class A common stock shares under the company’s Equity Incentive Plan. This change, approved at the recent AGM, reflects ongoing strategic efforts to align leadership incentives with company performance, potentially impacting stakeholder confidence and the company’s market positioning.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Medical Systems Announces Director’s Stock Acquisition

Imricor Medical Systems, Inc. announced a change in the director’s interest as Mr. Mark Tibbles acquired 41,280 Class A common stocks under the company’s Equity Incentive Plan. This acquisition, approved at the AGM on May 14, 2025, increases Mr. Tibbles’ total holdings to 6,272,193 shares, reflecting the company’s ongoing commitment to aligning management interests with shareholder value.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Announces Director’s Interest Change Under Equity Incentive Plan

Imricor Medical Systems, Inc. announced a change in the director’s interest, specifically for Mr. Peter McGregor, who acquired additional CHESS Depositary Interests (CDIs) under the company’s Equity Incentive Plan (EIP). This acquisition, approved at the recent AGM, reflects the company’s ongoing commitment to aligning director interests with shareholder value, potentially impacting its governance and stakeholder confidence positively.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Medical Systems Announces Quotation of New Securities

Imricor Medical Systems, Inc. announced the application for quotation of 121,260 securities under an employee incentive scheme on the Australian Securities Exchange. This move is part of the company’s strategy to enhance its market presence and incentivize its workforce, potentially impacting its operational capabilities and stakeholder engagement positively.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Medical Systems Reports Successful 2025 Annual Stockholders Meeting Outcomes

Imricor Medical Systems, Inc. announced the successful outcomes of its 2025 Annual Stockholders Meeting, where all resolutions were passed by a poll. This development underscores the company’s strategic direction and commitment to advancing its market presence in the MRI-compatible medical device sector. The meeting’s results are expected to bolster Imricor’s operational strategies and reinforce its positioning as a pioneer in the cardiac catheter ablation market, potentially impacting stakeholders positively by enhancing its growth prospects and market reach.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Medical Systems, Inc. 2025 AGM Highlights and Regulatory Compliance

Imricor Medical Systems, Inc. held its Annual General Meeting in May 2025, providing a general overview of the company’s activities and financial information. The presentation highlighted the company’s reliance on the safe harbor provisions of Regulation S under the US Securities Act for trading its CHESS Depositary Interests on the ASX. The release emphasized the importance of not placing undue reliance on forward-looking statements due to the current economic climate and the ongoing impact of the COVID-19 pandemic.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

Imricor Advances Global Expansion and Clinical Trials for MRI-Compatible Devices

Imricor Medical Systems, Inc. announced significant advancements in its operations and market reach, including regulatory approvals in Europe and the Middle East for its MRI-compatible ablation devices and the anticipated approval of its NorthStar MRI-native mapping and guidance system. The company is expanding its global commercialization efforts and has initiated clinical trials to support further FDA approvals and expanded indications. These developments are expected to enhance Imricor’s market positioning and unlock substantial value for stakeholders, including patients, physicians, and investors.

The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.28 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.